Unsere Publikationen

Efficacy of alemtuzumab over 6 years in relapsing–remitting multiple sclerosis patients who relapsed between courses 1 and 2: Post hoc analysis of the CARE-MS studies

Link
https://doi.org/10.1177/1352458519881759
Tags
Multiple SkleroseMS Behandlung
Jahr
2020
Autoren
Van Wijmeersch B, Singer BA, Boster A, Broadley S, Fernández Ó, Freedman MS, Izquierdo G, Lycke J, Pozzilli C, Sharrack B, Steingo B, Wiendl H, Wray S, Ziemssen T, Chung L, Margolin DH, Thangavelu K, Vermersch P.
Verlag
Mult Scler. 2020 Nov;26(13):1719-1728.
Zum Eintrag

The transitional phase of multiple sclerosis: The concept of PANGAEA 2.0 evolution study

Link
https://doi.org/10.1016/j.msard.2020.102523
Tags
Multiple SkleroseMS Behandlung
Jahr
2020
Autoren
Inojosa H, Rauser B, Ettle B, Ziemssen T.
Verlag
Mult Scler Relat Disord 2020;46.
Zum Eintrag

Long-term peripheral immune cell profiling reveals further targets of oral cladribine in MS

Link
https://doi.org/10.1002/acn3.51206
Tags
Multiple SkleroseMS Behandlung
Jahr
2020
Autoren
Moser T, Schwenker K, Seiberl M, Feige J, Akgün K, Haschke-Becher E, Ziemssen T, Sellner J.
Verlag
Ann Clin Transl Neurol. 2020 Nov;7(11):2199-2212.
Zum Eintrag

Efficacy of alemtuzumab in relapsing-remitting MS patients who received additional courses after the initial two courses: Pooled analysis of the CARE-MS, extension, and TOPAZ studies

Link
https://doi.org/10.1177/1352458519888610
Tags
Multiple SkleroseMS Behandlung
Jahr
2020
Autoren
Comi G, Alroughani R, Boster AL, Bass AD, Berkovich R, Fernández Ó, Kim HJ, Limmroth V, Lycke J, Macdonell RA, Sharrack B, Singer BA, Vermersch P, Wiendl H, Ziemssen T, Jacobs A, Daizadeh N, Rodriguez CE, Traboulsee A; CARE-MS I, CARE-MS II, CAMMS03409, and TOPAZ Investigators.
Verlag
Mult Scler. 2020 Dec;26(14):1866-1876.
Zum Eintrag

Quality of Life Improves with Alemtuzumab Over 6 Years in Relapsing-Remitting Multiple Sclerosis Patients with or without Autoimmune Thyroid Adverse Events: Post Hoc Analysis of the CARE-MS Studies

Link
https://doi.org/10.1007/s40120-020-00191-7
Tags
Multiple SkleroseMS Behandlung
Jahr
2020
Autoren
Bertolotto A, Arroyo R, Celius EG, Comi G, Havrdova EK, Honeycutt WD, Hunter SF, Izquierdo G, Kornek B, Miller T, Mitsikostas DD, Singer BA, Ziemssen T, Chung L, Daizadeh N, Afsar S, Hashemi L, Senior P.
Verlag
Neurol Ther. 2020 Dec;9(2):443-457.
Zum Eintrag

Long-term peripheral immune cell profiling reveals further targets of oral cladribine in MS

Link
https://doi.org/10.1002/acn3.51206
Tags
Multiple SkleroseMS Behandlung
Jahr
2020
Autoren
Moser T, Schwenker K, Seiberl M, Feige J, Akgün K, Haschke-Becher E, Ziemssen T, Sellner J.
Verlag
Ann Clin Transl Neurol. 2020 Nov;7(11):2199-2212.
Zum Eintrag

Ofatumumab versus Teriflunomide

Link
https://doi.org/10.1056/nejmoa1917246
Tags
Multiple SkleroseMS Behandlung
Jahr
2020
Autoren
Hauser SL, Bar-Or A, Cohen JA, Comi G, Correale J, Coyle PK, Cross AH, de Seze J, Leppert D, Montalban X, Selmaj K, Wiendl H, Kerloeguen C, Willi R, Li B, Kakarieka A, Tomic D, Goodyear A, Pingili R, Häring DA, Ramanathan K, Merschhemke M, Ziemssen T, Kappos L; ASCLEPIOS I and ASCLEPIOS II Trial Groups.
Verlag
N Engl J Med. 2020 Aug 6;383(6):546-557.
Zum Eintrag

Reasons to switch: a noninterventional study evaluating immunotherapy switches in a large German multicentre cohort of patients with relapsing-remitting multiple sclerosis

Link
https://doi.org/10.1177/1756286419892077
Tags
Multiple SkleroseMS Behandlung
Jahr
2019
Autoren
Mäurer M, Tiel-Wilck K, Oehm E, Richter N, Springer M, Oschmann P, Manzel A, Hieke-Schulz S, Zingler V, Kandenwein JA, Ziemssen T, Linker RA.
Verlag
Ther Adv Neurol Disord. 2019 Dec 19;12:1756286419892077.
Zum Eintrag

Publikationen durchsuchen

Publikationen filtern

Filter
Tags
Multiple Sklerose
MS Behandlung
Mobilität
Autonomes Nervensystem & Neuroendokrinologie
Neuroimmunologie
Herzratenvariabilität
Baroreflexsensitivität
Management & Science
eHealth
Gesundheitsökonomie
Andere
Zeige alleVerstecke
Jahr
-